Treatment of SARS-CoV-2 relapse with remdesivir and neutralizing antibodies cocktail in a patient with X-linked agammaglobulinaemia.

Authors :: Palomba E
Carrabba M
Zuglian G
Alagna L
Saltini P
Fortina V
Hu C
Bandera A
Fabio G
Gori A
Muscatello A
Source :: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases [Int J Infect Dis] 2021 Sep; Vol. 110, pp. 338-340. Date of Electronic Publication: 2021 Jul 28.
Publication Year :: 2021
Abstract: During the coronavirus disease 2019 (COVID-19) pandemic, patients with humoral immunodeficiency are at higher risk of developing chronic infection and having a negative outcome. Few data are available on therapeutic options for this population. This case report discusses the treatment of disease relapse with remdesivir and monoclonal antibodies in an adult patient with X-linked agammaglobulinaemia.<br />Competing Interests: Conflict of interest statement None declared.<br /> (Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.)

Subjects :: Adenosine Monophosphate analogs & derivatives
Adult
Agammaglobulinemia
Alanine analogs & derivatives
Antibodies, Neutralizing
Antibodies, Viral
Genetic Diseases, X-Linked
Humans
Recurrence
SARS-CoV-2
COVID-19 Drug Treatment

Language :: English
ISSN :: 1878-3511
Volume :: 110
Database :: MEDLINE
Journal :: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
Publication Type :: Academic Journal
Accession number :: 34332085
Full Text :: https://doi.org/10.1016/j.ijid.2021.07.064

Full Text Access

Tools